An established research ecosystem, a distinctive business community, and talented and competent individuals are requirements for a top medtech site. Nova Scotia (NS) is the ideal location and size to test and trial innovative methods of providing care using new technology and therapies since it is research-focused.
Nova Scotia is also known for its thriving medical technology industry. With a plethora of facilities and agencies dedicated to healthcare innovation, this province is a hub for cutting-edge research, development, and deployment of advanced medical technologies.
The largest in Atlantic Canada, Nova Scotia Health is the province’s unified health authority and runs hospitals, clinics, and community-based programs all over the territory. Nova Scotia Health is evolving into a preferred partner for businesses with cutting-edge solutions thanks to its focus on decentralized clinical trials and health system change.
The Canadian Institute for Vaccinology specializes in the study of infectious diseases and has participated in hundreds of vaccination clinical trials sponsored by the vaccine industry.
The Brain Repair Center focuses in treating a wide range of problems resulting from brain and nervous system illnesses. New therapies that can benefit and save the lives of those who are afflicted are the main focus of their study.
One of the most educated workforces, the highest concentration of colleges per person in North America, and a close-knit business and public health community may all be found in Nova Scotia. The province is able to immediately link businesses with decision makers because it is a smaller province. This means that both locally and worldwide, NS has the resources necessary to nurture and support a burgeoning medtech sector for businesses like NovaResp Technologies and Mimosa.
The founder and CEO of NovaResp Technologies, Hamed Hanafi, is an assistant professor at Dalhousie University, which is one of Canada’s top research universities and the largest university in Atlantic Canada. To significantly increase patient comfort and adherence to therapy for those with obstructive sleep apnea (OSA), NovaResp has created patented software that is compatible with any positive airway pressure (PAP) machine. During PAP therapy, the company’s platform software combines artificial intelligence and machine learning to anticipate and stop apnea episodes before they happen.
Hanafi considers herself fortunate to have founded NovaResp in Nova Scotia. She moved to Halifax over 16 years ago and have called it “home” ever since. She also added that the entrepreneurial ecosystem in Nova Scotia is influenced by the people’s friendliness and kindness. “Everyone is ready to help and happy to see you and your business grow”, she said.
MIMOSA Diagnostics, a company using a revolutionary method to skin imaging by enabling clinicians to look beneath the skin’s surface, is led by Dr. Karen Cross, its CEO and co-founder. “Double Doctor” Dr. Cross has spent more than 22 years developing technology to evaluate tissue injury. He is a plastic and reconstructive surgeon with a PhD in optical imaging and wound healing.
Dr. Cross shared that their team at MIMOSA Diagnostics aspired to participate in Halifax’s growth as a budding center for the medical technology industry. As a result of genuine alignment amongst stakeholders at all levels, including the government, health authorities, and physicians, Nova Scotia is in a unique position in the medtech industry.
Reference and photo credits to: